1.Application of reimplantation technique in treating Marfan syndrome and giant aortic root aneurysm during mid-pregnancy: A case report
NIU ; Hong QIAN ; Haibo SONG ; Lei DU ; Hai YU ; Eryong ZHANG ; Zhenghua XIAO
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2025;32(03):416-420
Pregnancy complicated by aortic root aneurysm in patients with Marfan syndrome is one of the main causes of termination of pregnancy or even death in pregnant women. A very small number of pregnant women require cardiac surgery to preserve pregnancy under extracorporeal circulation, and all surgeries use aortic root replacement. We reported a 30-year-old patient with severe aortic regurgitation combined with giant aortic root aneurysm and Marfan syndrome in mid-pregnancy. Valve-sparing root replacement using reimplantation technology was performed via a multidisciplinary cooperation model. This not only achieved the patient’s desire to continue pregnancy but also avoided the anticoagulation and bleeding complications brought by mechanical valve replacement, reduced pregnancy risks and improved long-term quality of life. Postoperative echocardiography showed a small amount of aortic valve regurgitation, aortic valve coaptation height of 0.6 cm, effective height of 1.1 cm, maximum aortic flow velocity of 1.4 m/s, mean transvalvular pressure gradient of 4.4 mm Hg, and satisfactory clinical results.
2.Causal relationship between gout and Alzheimer's disease: a two-sample Mendelian randomization analysis
Chuijia KONG ; Ying ZHANG ; Zhenkun TAN ; Junjiao PING ; Haibo ZHANG ; Jie ZHANG ; Jiali LUO ; Xinxia LIU
Sichuan Mental Health 2025;38(2):115-122
BackgroundDementia seriously affects the quality of life and lifespan of elderly people, with Alzheimer's disease (AD) being the most common type of dementia. Previous studies have suggested that gout may reduce the risk of developing AD, but the causal relationship between the two still requires further research. ObjectiveTo investigate the potential causal relationship between gout and AD through a two-sample Mendelian randomization (MR) analysis, so as to provide references for the prevention and treatment of AD. MethodsData from Genome-Wide Association Studies (GWAS) extracted in 2024 were analyzed, using pooled data on gout (6 810 cases in the case group and 477 788 cases in the control group) published by UK Biobank in 2021 as the exposure variable, and data on AD (3 899 cases in the case group and 214 893 cases in the control group) published by FinnGen in the same year as the outcome variable. The inverse-variance weighted, MR-Egger regression, weighted median estimation, simple model and weighted model were used to analyze the potential causal relationship between gout and AD. Pleiotropic effects were assessed using MR-Egger regression. Heterogeneity assessment was conducted using Cochran's Q test. The leave-one-out analysis was carried out for sensitivity analysis. And a funnel plot was drawn to detect potential publication bias. ResultsThe inverse-variance weighted analysis demonstrated a negative causal relationship between gout and AD (OR=0.004, 95% CI: 0~0.700, P<0.05). The plot resembled a symmetrical inversed funnel, indicating the absence of publication bias. No heterogeneity was detected by Cochran's Q test. The MR-Egger regression indicated no significant horizontal pleiotropy. Concerning the reverse directions, no significant associations between AD and gout were noted. ConclusionThere is a negative causal relationship between gout and AD, with gout potentially reducing the risk of developing AD. [Funded by The Third Batch of Social Welfare and Basic Research Projects (Medical and Health) of Zhongshan City in 2022 (number, 2022B3017)]
3.Current Status and Optimization Strategies for Investigator Initiated Trial on Traditional Chinese Medicine in the Treatment of Malignant Tumors Conducted by Western Medicine Institutions
Xuechen GENG ; Yanmei LIU ; Qianqian BU ; Qinchang ZHANG ; Dong ZHANG ; Yuquan TAO ; Liu LI ; Ling LI ; Haibo CHENG
Journal of Traditional Chinese Medicine 2025;66(9):878-882
Investigator initiated trial (IIT) represents a primary format for clinical research in traditional Chinese medicine (TCM). As key implementation sites for TCM-based IIT targeting malignant tumors, western medicine institutions often face unique challenges in conducting such studies, which limit their feasibility and standardization. This paper reviews the registration status of TCM-based IIT for malignancies conducted in western medical institutions and analyzes key difficulties, including complex project initiation and management processes, limited TCM knowledge and skills among western medicine physicians, and relatively low patient acceptance of TCM. From a practical perspective, the study proposes several optimization strategies. These include improving the review and management mechanisms of TCM-related IIT within western medical institutions, establishing multidisciplinary clinical research teams that integrate TCM and western medicine, and enhancing investigators' training in TCM theory and clinical skills. Additionally, the study suggests standardizing IIT operational procedures, objectifying the collection of TCM diagnostic information, refining subject recruitment methods, and increasing TCM involvement in patient follow-up and management. These investigator-oriented, TCM-featured, and operable strategies aim to promote the high-quality development of TCM-based IIT in western medicine institutions and enhance the clinical application of TCM.
4.Treatment strategy after neoadjuvant PD-1 inhibitor combined with chemotherapy for patients with locally advanced esophageal squamous cell carcinoma
Shifa ZHANG ; Haibo CAI ; Liji CHEN
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2025;32(02):216-222
Objective To investigate the necessity of further surgery for patients with locally advanced esophageal squamous cell carcinoma following treatment with the programmed cell death-1 (PD-1) inhibitor combined with chemotherapy, and to assess its impact on survival. Methods Patients with stage ⅡA to ⅢB esophageal squamous cell carcinoma who received immunotherapy combined with chemotherapy at our hospital from January 2020 to June 2022 were selected for this study. Based on whether they underwent surgery after receiving PD-1 inhibitor combined with chemotherapy, patients were divided into a surgery group and a non-surgery group. We compared the general clinical data, side effects, clinical complete response rates, progression-free survival (PFS), and overall survival (OS) between the two groups. Results A total of 58 patients were included in the study, comprising 45 males and 13 females, with an average age of (65.5±6.9) years. There were no statistical differences in general clinical data or adverse reactions between the two groups. Univariate analysis revealed that the objective response rate and surgery were significantly associated with PFS (P<0.05). Binary logistic regression analysis showed that surgery was the only independent risk factor for PFS (P=0.003). Kaplan-Meier survival analysis showed that the PFS and OS in the surgery group were significantly higher than those in the non-surgery group (HR=0.13, 95%CI 0.036 to 0.520, P<0.001; HR=0.17, 95%CI 0.045 to 0.680, P=0.004). Conclusion After treatment with the PD-1 inhibitor combined with chemotherapy, patients with locally advanced esophageal squamous cell carcinoma still require surgical intervention to achieve improved PFS and OS.
5.Plasma Metabolomic Analysis of Colorectal Cancer Patients with Spleen-Qi Deficiency and Damp-heat Stasis-toxin Syndrome Based on UPLC-Q-Exactive-Orbitrap-MS
Siting MENG ; Lihuiping TAO ; Dong ZHANG ; Qinchang ZHANG ; Yiping FAN ; Haibo CHENG
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(21):130-137
ObjectiveTo observe and analyze the plasma metabolite differences among colorectal cancer patients with spleen-qi deficiency, damp-heat stasis-toxin syndrome(SRYD), non-spleen-qi deficiency, damp-heat stasis-toxin syndrome(non-SRYD), and normal human beings(Normal), aiming to identify unique metabolites specific to SRYD colorectal cancer patients and their potential biomarkers. MethodsBased on the diagnostic criteria of SRYD and non-SRYD colorectal cancer, 30 patients were included, including 10 patients with SRYD colorectal cancer and 20 patients with non-SRYD colorectal cancer, while 10 individuals were recruited for the Normal group. Metabolome sequencing of plasma from the three groups was performed by ultra-performance liquid chromatography-quadrupole-electrostatic field orbitrap mass spectrometry(UPLC-Q-Exactive-Orbitrap-MS). Multivariate statistical analysis were performed by principal component analysis(PCA) and partial least squares-discriminant analysis(PLS-DA), and the intergroup differential metabolites were identified based on variable importance in the projection(VIP) value>1 and t-test P<0.05. And pathway enrichment analysis based on Kyoto Encyclopedia of Genes and Genomes(KEGG) was performed to explore the metabolites and metabolic pathways specific to SRYD colorectal cancer patients. ResultsMetabolome sequencing results showed some differences in metabolic profiles between the groups. A total of 111 plasma differential metabolites were found in the SRYD group and the Normal group, of which 31 were up-regulated and 80 were down-regulated, mainly including stearoyl lysophosphatidylcholine, indole-3-acrylic acid, and dehydroepiandrosterone sulfate(P<0.05). The non-SRYD group exhibited 97 differentially expressed metabolites compared to the Normal group, with 36 up-regulated and 61 down-regulated, mainly including stearoyl lysophosphatidylcholine, sphingosine, and palmitoyl lysophosphatidylcholine(P<0.05). And the SRYD group exhibited 19 differentially expressed metabolites compared to the non-SRYD group, of which 5 were up-regulated and 14 were down-regulated, mainly including dihydrosphingosine, palmitic acid, and linoleoylethanolamide(P<0.05). The significant differential metabolites were subjected to KEGG analysis to obtain significantly enriched metabolic pathways in each group, and the results showed that 11 metabolic pathways such as primary bile acid synthesis, cholesterol metabolism and bile secretion were differential signaling pathways specific to SRYD colorectal cancer. Further retrieval of the above key signaling pathways showed that bile acids were up-regulated in both bile secretion and primary bile acid synthesis pathways, and there was a trend of up-regulation of glycochenodeoxycholic acid, taurochenodeoxycholic acid, and chenodeoxycholic acid. ConclusionPrimary bile acid synthesis, cholesterol metabolism, and bile secretion-related pathways may be differential signaling pathways specific to SRYD colorectal cancer, and bile acid is a core molecule in the metabolic pathway, which can serve as potential biomarkers closely related to the development and progression of SRYD colorectal cancer.
6.Plasma Metabolomic Analysis of Colorectal Cancer Patients with Spleen-Qi Deficiency and Damp-heat Stasis-toxin Syndrome Based on UPLC-Q-Exactive-Orbitrap-MS
Siting MENG ; Lihuiping TAO ; Dong ZHANG ; Qinchang ZHANG ; Yiping FAN ; Haibo CHENG
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(21):130-137
ObjectiveTo observe and analyze the plasma metabolite differences among colorectal cancer patients with spleen-qi deficiency, damp-heat stasis-toxin syndrome(SRYD), non-spleen-qi deficiency, damp-heat stasis-toxin syndrome(non-SRYD), and normal human beings(Normal), aiming to identify unique metabolites specific to SRYD colorectal cancer patients and their potential biomarkers. MethodsBased on the diagnostic criteria of SRYD and non-SRYD colorectal cancer, 30 patients were included, including 10 patients with SRYD colorectal cancer and 20 patients with non-SRYD colorectal cancer, while 10 individuals were recruited for the Normal group. Metabolome sequencing of plasma from the three groups was performed by ultra-performance liquid chromatography-quadrupole-electrostatic field orbitrap mass spectrometry(UPLC-Q-Exactive-Orbitrap-MS). Multivariate statistical analysis were performed by principal component analysis(PCA) and partial least squares-discriminant analysis(PLS-DA), and the intergroup differential metabolites were identified based on variable importance in the projection(VIP) value>1 and t-test P<0.05. And pathway enrichment analysis based on Kyoto Encyclopedia of Genes and Genomes(KEGG) was performed to explore the metabolites and metabolic pathways specific to SRYD colorectal cancer patients. ResultsMetabolome sequencing results showed some differences in metabolic profiles between the groups. A total of 111 plasma differential metabolites were found in the SRYD group and the Normal group, of which 31 were up-regulated and 80 were down-regulated, mainly including stearoyl lysophosphatidylcholine, indole-3-acrylic acid, and dehydroepiandrosterone sulfate(P<0.05). The non-SRYD group exhibited 97 differentially expressed metabolites compared to the Normal group, with 36 up-regulated and 61 down-regulated, mainly including stearoyl lysophosphatidylcholine, sphingosine, and palmitoyl lysophosphatidylcholine(P<0.05). And the SRYD group exhibited 19 differentially expressed metabolites compared to the non-SRYD group, of which 5 were up-regulated and 14 were down-regulated, mainly including dihydrosphingosine, palmitic acid, and linoleoylethanolamide(P<0.05). The significant differential metabolites were subjected to KEGG analysis to obtain significantly enriched metabolic pathways in each group, and the results showed that 11 metabolic pathways such as primary bile acid synthesis, cholesterol metabolism and bile secretion were differential signaling pathways specific to SRYD colorectal cancer. Further retrieval of the above key signaling pathways showed that bile acids were up-regulated in both bile secretion and primary bile acid synthesis pathways, and there was a trend of up-regulation of glycochenodeoxycholic acid, taurochenodeoxycholic acid, and chenodeoxycholic acid. ConclusionPrimary bile acid synthesis, cholesterol metabolism, and bile secretion-related pathways may be differential signaling pathways specific to SRYD colorectal cancer, and bile acid is a core molecule in the metabolic pathway, which can serve as potential biomarkers closely related to the development and progression of SRYD colorectal cancer.
7.The role of gut microbiota homeostasis in the occurrence and development of hepatocellular carcinoma and targeted intervention strategies
Yan CUI ; Junzhe JIAO ; Ruijuan YAN ; Shuguang YAN ; Hailiang WEI ; Zhanjie CHANG ; Haibo ZHANG ; Jingtao LI
Journal of Clinical Hepatology 2025;41(9):1913-1919
Hepatocellular carcinoma (HCC), as the sixth most common malignant tumor worldwide, poses a serious threat to human health due to its insidious onset and high mortality rate. This article reviews the molecular mechanisms and intervention strategies of gut microbiota (GM) homeostasis in the development and progression of HCC, in order to provide new ideas for the intervention and treatment of HCC. Studies have shown that GM dysbiosis, intestinal leakage, microbial-associated molecular pattern, bacterial translocation, and metabolic products play key roles in the progression of HCC. GM imbalance may lead to immune escape, thereby promoting tumor cell proliferation and metastasis. This article elaborates on the association between GM and HCC, deeply analyzes the mechanism of action of GM in the development and progression of HCC, investigates the role of bile acid-related metabolites, short-chain fatty acid-related metabolites, and other metabolites in HCC, and explores the strategies for targeting GM in the treatment of HCC, including probiotics, prebiotics, antibiotics, Toll-like receptor 4 antagonists, and fecal microbiota transplantation. This article emphasizes that maintaining the integrity of the intestinal barrier and GM homeostasis is of great significance in the prevention and treatment of HCC, which provides a direction for developing new diagnosis and treatment strategies.
8.Discussion on the Core Pathogenesis and Prevention and Treatment Strategy for Postoperative Recurrence of Colorectal Cancer from the Spatiotemporal Evolution of the Cancer Toxin Theory
Xuechen GENG ; Liu LI ; Qinchang ZHANG ; Qianqian BU ; Haibo CHENG
Journal of Traditional Chinese Medicine 2025;66(15):1538-1542
According to the theory of cancer toxin pathogenesis, tumors are complex syndromes centered on cancer toxin, characterized by multiple time points and locations, interwoven pathogenic toxins, and a combination of deficiency and excess. Postoperative recurrence of colorectal cancer is a dynamic spatiotemporal process. In this paper, the core pathogenesis of postoperative recurrence of colorectal cancer, namely "deficiency of spleen qi, with damp-heat stasis toxin", has been discussed based on spatiotemporal evolution of cancer toxin. It is suggested that spleen qi depletion leading to the proliferation of cancer toxin represents the temporal characteristic of postoperative recurrence, while the stasis of damp-heat facilitating the aggregation and spread of cancer toxin refelct its spatial pattern. This paper has constructed a holistic spatiotemporal prevention and treatment strategy according to different stages before and after recurrence. Before recurrence, the focus is on prevention, and it is suggested to rectify the healthy qi and fortify spleen, clear heat and resolve dampness, unblock collaterals and remove toxin. After recurrence, the focus should be on treatment, and the strategy is combating cancer and removing toxin, breaking the blood to eliminate disease, regulating and tonifying the zang-fu (脏腑) organs.
9.Effect of Scutellariae Radix Combined with EGFR-TKIs on Non-small Cell Lung Cancer
Yaya YU ; Chenjing LEI ; Zhenzhen XIAO ; Qi MO ; Changju MA ; Lina DING ; Yadong CHEN ; Yanjuan ZHU ; Haibo ZHANG
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(18):106-115
ObjectiveTo investigate the effects of Scutellariae Radix combined with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) on cell proliferation, apoptosis, cancer stem cell (CSC) marker expression, and metabolism in non-small cell lung cancer (NSCLC) cells. MethodsThe anti-tumor effects of Scutellariae Radix and EGFR-TKIs (gefitinib or osimertinib) in NSCLC cells were evaluated using the cell counting kit-8 (CCK-8) and Annexin V-FITC/propidium iodide (PI) double staining apoptosis assay. The activity of Scutellariae Radix and EGFR-TKIs in three-dimensional (3D) cultures of NSCLC cells was assessed using the CellTiter-Glo® 3D cell viability assay. The mRNA and protein expression levels of CSC markers, sex determining region y box protein 2 (SOX2) and aldehyde dehydrogenase 1 family member A1 (ALDH1A1), were detected by quantitative real-time polymerase chain reaction (Real-time PCR) and Western blot, respectively. Changes in intracellular reactive oxygen species (ROS) levels were detected by ROS staining, and the redox ratio was detected by femtosecond laser labeling free imaging (FLI). ResultsUnder both two-dimensional (2D) and 3D culture conditions, compared with the blank group and EGFR-TKI group, the combination group showed significantly reduced cell viability and increased apoptosis rate (P<0.05). Compared with the EGFR-TKI group, the mRNA and protein levels of CSC markers were significantly downregulated in the combination group (P<0.05). Additionally, the redox ratio was significantly elevated (P<0.05), and ROS levels were also increased in the combination group compared with the EGFR-TKI group. ConclusionIn NSCLC cells, Scutellariae Radix enhances the redox ratio and increases ROS levels, thereby inhibiting the expression of CSC markers and strengthening the anti-tumor effects of EGFR-TKIs. This provides a novel molecular mechanism by which Scutellariae Radix may enhance the sensitivity of targeted therapies.
10.Research progress on PD-1/PD-L1 inhibitors in neoadjuvant therapy for esophageal cancer
Liji CHEN ; Hongmei MA ; Shifa ZHANG ; Kaize ZHONG ; Dongbao YANG ; Jiuhe SUN ; Hongfeng LIU ; Ru SONG ; Jishan ZHANG ; Haibo CAI
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2025;32(05):714-721
Esophageal cancer is one of the malignant tumors that poses a threat to human health, with both high incidence and malignancy. Currently, surgery following neoadjuvant chemoradiotherapy is the standard treatment for locally advanced esophageal cancer; however, the long-term prognosis remains unsatisfactory. In recent years, inhibitors of programmed death protein-1 (PD-1) and its ligand (programmed death ligand-1, PD-L1) have achieved breakthrough progress in other solid tumors, and research on esophageal cancer is gradually being conducted. With the demonstration of good efficacy of PD-1/PD-L1 inhibitors in the first-line and second-line treatment of advanced unresectable esophageal cancer, their incorporation into neoadjuvant treatment regimens has become a hot topic. Therefore, this article reviews the mechanism of action of PD-1/PD-L1 inhibitors and their application in the neoadjuvant treatment of esophageal cancer.

Result Analysis
Print
Save
E-mail